Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.60 |
| ▸ | HTR2C | P28335 | 6/20 | 0.57 |
| ▸ | HTR2A | P28223 | 3/20 | 0.57 |
| ▸ | HTR2B | P41595 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.53 |
| ▸ | HTR3B | O95264 | 1/20 | 0.53 |
| ▸ | HTR1D | P28221 | 1/20 | 0.53 |
| ▸ | HTR3A | P46098 | 1/20 | 0.53 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.53 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 2/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15686367 | 0.84 | POLB (0.50) | HTR2CHTR2AHTR2BALDH1A1HTR3E | |
| SCHEMBL7242369 | 0.80 | OPRM1 (0.46) | OPRM1HTR2CHTR2AHTR2BALDH1A1 | |
| SCHEMBL7238013 | 0.79 | OPRM1 (0.66) | OPRM1HTR2CHTR2AHTR2BALDH1A1 | |
| SCHEMBL7239902 | 0.74 | OPRM1 (0.62) | OPRM1HTR2CHTR2AHTR2BHTR3E | |
| SCHEMBL19838619 | 0.74 | OPRM1 (0.62) | OPRM1HTR2CHTR2AHTR2BHTR3E | |
| SCHEMBL19640795 | 0.74 | AKR1C3 (0.55) | — | |
| SCHEMBL6496670 | 0.74 | OPRM1 (0.67) | OPRM1HTR2AALDH1A1SIGMAR1MEN1 | |
| SCHEMBL17793694 | 0.73 | ADRB1 (0.55) | HTR2CHTR2AHTR2BALDH1A1MAPT | |
| SCHEMBL18452497 | 0.73 | HTR2C (1.00) | HTR2CHTR2AHTR2BALDH1A1HTR3E | |
| SCHEMBL22813701 | 0.73 | HTR2C (0.42) | OPRM1HTR2CHTR2AHTR2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-08-11 | — | — | US | claimed |
| US-20050209216-A1 | Phenyl-and pyridyl-diazaheterocycles having a tnf-modulating activity | SANOFI-AVENTIS (FR) | 2005-09-22 | — | — | US | disclosed |
| EP-1517896-A2 | PHENYL- AND PYRIDYL-DIAZAHETEROCYCLES HAVING A TNF-MODULATING ACTIVITY | Sanofi-Aventis (FR) | 2005-03-30 | — | — | EP | disclosed |
| WO-2003106425-A2 | PHENYL- AND PYRIDYL-DIAZAHETEROCYCLES HAVING A TNF-MODULATING ACTIVITY | SANOFI-SYNTHELABO (FR) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | REN, AGTR1, ACE | OPRM1 3696/4885HTR2C 1600/4885HTR2A 3307/4885 |
| US-20050209216-A1 | Phenyl-and pyridyl-diazaheterocycles having a tnf-modulating activity | TNF, TNFRSF1A, CD40 | OPRM1 221/4885HTR2C 472/4885HTR2A 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.